Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. / Torekov, Signe Sørensen; Kipnes, M S; Harley, R E; Holst, J J; Ehlers, M R.

I: Diabetes, Obesity and Metabolism, Bind 13, Nr. 7, 2011, s. 639-43.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Torekov, SS, Kipnes, MS, Harley, RE, Holst, JJ & Ehlers, MR 2011, 'Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, bind 13, nr. 7, s. 639-43. https://doi.org/10.1111/j.1463-1326.2011.01388.x

APA

Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R. (2011). Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 13(7), 639-43. https://doi.org/10.1111/j.1463-1326.2011.01388.x

Vancouver

Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2011;13(7):639-43. https://doi.org/10.1111/j.1463-1326.2011.01388.x

Author

Torekov, Signe Sørensen ; Kipnes, M S ; Harley, R E ; Holst, J J ; Ehlers, M R. / Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. I: Diabetes, Obesity and Metabolism. 2011 ; Bind 13, Nr. 7. s. 639-43.

Bibtex

@article{5c758032844348d99fd1015debedeebf,
title = "Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes",
abstract = "To evaluate the dose-response relationship of the recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11-h serum glucose profiles.",
keywords = "Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Infusions, Subcutaneous, Male, Middle Aged, Peptide Fragments, Placebos, Postprandial Period",
author = "Torekov, {Signe S{\o}rensen} and Kipnes, {M S} and Harley, {R E} and Holst, {J J} and Ehlers, {M R}",
note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",
year = "2011",
doi = "10.1111/j.1463-1326.2011.01388.x",
language = "English",
volume = "13",
pages = "639--43",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes

AU - Torekov, Signe Sørensen

AU - Kipnes, M S

AU - Harley, R E

AU - Holst, J J

AU - Ehlers, M R

N1 - © 2011 Blackwell Publishing Ltd.

PY - 2011

Y1 - 2011

N2 - To evaluate the dose-response relationship of the recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11-h serum glucose profiles.

AB - To evaluate the dose-response relationship of the recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered by continuous subcutaneous infusion (CSCI) in subjects with type 2 diabetes, with respect to reductions in fasting, postprandial and 11-h serum glucose profiles.

KW - Blood Glucose

KW - C-Peptide

KW - Diabetes Mellitus, Type 2

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Female

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Hypoglycemic Agents

KW - Infusions, Subcutaneous

KW - Male

KW - Middle Aged

KW - Peptide Fragments

KW - Placebos

KW - Postprandial Period

U2 - 10.1111/j.1463-1326.2011.01388.x

DO - 10.1111/j.1463-1326.2011.01388.x

M3 - Journal article

C2 - 21362122

VL - 13

SP - 639

EP - 643

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 7

ER -

ID: 40246465